Jun-ichi Iga

Has grant

Professor

Ehime University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Jun-ichi Iga is an Associate Professor at Ehime University in Japan. His research focuses on the efficacy of psychotropic medications, including studies on major depressive disorder and treatment-resistant schizophrenia. Recent publications examine topics such as impulsivity in borderline personality disorder, emotional blunting, and gene expression changes related to mental health conditions.

Recent Grants

Grant: Close

Research on neuropsychiatric disorders in the elderly focusing on the phenomenon of cellular senescence

Open Date: 2022-04-01

Close Date: 2024-03-01

Grant: Close

Blood biomarker for differentiating geriatric depression from Alzheimer's disease

Open Date: 2018-04-01

Close Date: 2021-03-01

Grant: Close

Association between early life adversity and 5HTT mRNA expression and DNA methylation in leukocytes of MDD

Open Date: 2015-04-01

Close Date: 2018-03-01

Grant: Close

Biological diagnostic test for major depressive disorder based on the leukocytes gene expression

Open Date: 2011-04-01

Close Date: 2012-12-01

Grant: Close

Molecular asseessment of PDLIM5 in MDD

Open Date: 2006-04-01

Close Date: 2008-03-01

Articles (35)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Background: Overall, 20% of patients with major depressive disorder (MDD) are treatment-resistant and do not respond to multiple antidepressant monotherapies. For such patients, augmentation therapy with antipsychotics is one of the therapeutic options. However, the mechanism of augmentation therapy is essentially unknown. Aim: This study aimed to elucidate the mechanism of brexpiprazole (BREX) augmentation at gene expression levels. Methods: Vehicle, escitalopram (ES), BREX, and ES + BREX (augmentation therapy) were administered to mouse neuroblastoma (Neuro2a) cells and submitted to RNA-sequencing. Gene expressions were also measured in the whole blood of MDD patients and the frontal cortices and hippocampi of mice after treatment for 20 days. Results: On RNA-seq and gene ontology analyses, upregulation of mitochondria (MT)-related genes was confirmed by quantitative Polymerase Chain Reaction (PCR). These upregulated genes were successfully validated in both Neuro2a and Caco2 cells. Decreased MT-ATP8 expression was found in the whole blood of MDD patients. Furthermore, changes in MT-mRNA expression were confirmed in the frontal cortices and hippocampi of mice with augmentation therapy. Conclusions: BREX augmentation modified MT-mRNA expressions in both in vitro and in vivo experiments. This may be a key finding in improving our understanding of MDD pathogenesis and clinical practice.

Year:

2025

Background and hypothesis The rate of antipsychotic polypharmacy is high. One risk factor for antipsychotic polypharmacy may be the severity of schizophrenia, including treatment-resistant schizophrenia (TRS). We hypothesized that the institutions that are able to prescribe clozapine present differences in pharmacological treatment even before TRS is diagnosed. Study Design A total of 8155 patients with schizophrenia were divided into the clozapine-available institution (CAI) group and the clozapine-unavailable institution (CUI) group. The psychotropic prescription rates at discharge were compared between the two groups. Furthermore, to investigate whether the diagnosis of TRS subgroups influenced treatment efficacy, we compared CAIs and CUIs with descriptions of subgroups with TRS (DSTRS) and those without descriptions of subgroups with TRS (NDSTRS). Results Compared to the CUI group, the rates of both antipsychotic monotherapy (58.3% vs. 50.7%; P = 2.4 × 10−7) and antipsychotic monotherapy without the concomitant use of other psychotropics (20.4% vs. 15.6%; P = 3.8 × 10−5) were significantly higher in the CAI group. The rate of antipsychotic monotherapy in the CAI with DSTRS group (63.3%) was significantly higher than that in the CAI with NDSTRS group (54.5%; P = 1.4 × 10−12), the CUI with DSTRS group (49.6%; P = 4.9 × 10−9), and the CUI with NDSTRS group (50.9%; P = 2.0 × 10−8). The rate of antipsychotic monotherapy without the concomitant use of other psychotropics in the CAI with DSTRS group (22.6%) was also significantly higher than that in the CAI with NDSTRS group (18.7%; P = 4.7 × 10−4), the CUI with DSTRS group (15.9%; P = 5.5 × 10−4), and the CUI with NDSTRS group (15.2%; P = 8.0 × 10−5). There was no significant difference in these rates between the other groups. Conclusions Both the availability of clozapine prescriptions and the precise diagnosis of TRS subgroups at discharge can promote the development of an organizational culture that facilitates the treatment of patients with schizophrenia.

Year:

2025

Year:

2025

Aim Recent studies have implicated autophagy in both weight regulation and depression. This study aimed to investigate the relationship between stress‐induced weight loss and autophagy‐related gene expression in a mouse model of depression. Method Male C57BL/6 mice were subjected to a chronic immobilization stress (CIS) protocol for 14 days to induce depressive‐like behavior. Body weight was measured before and after the CIS, and depressive‐like behavior was assessed using the tail suspension test (TST). The expression levels of autophagy‐related genes ( Atg5 , Atg7 , Atg12 , Becn1 , Mmp9 , Fkbp5 , and Map1lc3b ) in the hippocampus and midbrain were evaluated using reverse transcription‐quantitative PCR (RT‐qPCR). Serum cortisol levels were also measured. Results The CIS resulted in significant weight loss and increased immobility time in the TST, indicating depressive‐like behavior. Serum cortisol levels were not different between CIS‐depression model and control mice. In the hippocampus, the expression levels of Fkbp5 , Mmp9 , and Map1lc3b were significantly higher in CIS‐depression model mice than in control mice. In the midbrain, the expression levels of Fkbp5 and Mmp9 were significantly higher in CIS‐depression model mice than in control mice. Increased autophagy‐related gene expressions in CIS‐depression model mice were consistent with the previous studies in the postmortem brains of patients with depression. A significant negative correlation was also found between Fkbp5 mRNA expression in the hippocampus and the weight change ratio before and after the CIS. Conclusion The findings suggest that enhanced autophagy may be related to the pathology of depression and that Fkbp5, an autophagy regulator, mediates stress‐induced weight loss.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (13)

Akihide Takeuchi

Professor & Chairperson

Kyoto Prefectural University of Medicine

JAPAN
View details

Motohiro Okada

Hirosaki University

JAPAN
View details

Shu-ichi Ueno

Professor

Ehime University Graduate School of Medicine

JAPAN
View details

Tetsuya Maeda

Iwate Medical University

JAPAN
View details

Tomoyasu Wakuda

Senior Assistant Professor

Hamamatsu University School of Medicine

JAPAN
View details

Kentaro Kawabe

Ehime University

JAPAN
View details

Shinichiro Ochi

Ehime University

JAPAN
View details

Masakatsu Yamashita

-

JAPAN
View details

Yoshihiko Furuta

Kyushu University

JAPAN
View details

Takanori Honda

Researcher

Kyushu University Graduate School of Medical Sciences

JAPAN
View details

Kenta Ide

University of Occupational and Environmental Health Japan

JAPAN
View details

Yusuke Inoue

Kyoto University

JAPAN
View details

Kenjiro Ono

Kanazawa University Graduate School of Medical Sciences

JAPAN
View details